Uncover the revolutionary potential of TAT-Cx43
TAT-Cx43 is a patented peptide developed by the Neurobiochemistry Lab at INCYL under the leadership of Dr. Arantxa Tabernero. Our research highlights TAT-Cx43’s ability to inhibit the oncogenic activity of Src. This innovative peptide exerts anti-tumor effects in different preclinical models of glioblastoma, including fresh specimens from glioblastoma patients, and enhances survival in glioblastoma-bearing mice. TAT-Cx43 offers promising prospects in the fight against glioblastoma, the most common and deadly brain brain tumor. Explore our findings to uncover this transformative approach to brain tumor therapy.
Funded Research:
